WASHINGTON, November 29, 2022 /PRNewswire/ — The PhRMA Foundation today announced the appointment to the Board of Directors of Aida HabtezionMD, Chief Medical Officer at Pfizer, Maha Radhakrishnan, MD, Chief Medical Officer at Biogen, George AddonPhD, Senior Vice President and Head of Discovery, Preclinical and Translational Medicine at Merck Research Laboratories, ed Lori Reilly, EsqChief Operating Officer at PhRMA.
The PhRMA Foundation is a 57-year-old non-profit organization that advances biopharmaceutical innovation and value-driven healthcare by investing in the frontiers of research. The Foundation catalyzes the careers of promising researchers through competitive, peer-reviewed grants and grants.
“These new board members bring to the PhRMA Foundation a diversity of experience and perspective that is critical as we enter the next era of change for the biopharmaceutical industry,” said Amy M Miller, PhD, president of the PhRMA Foundation. “I look forward to working with our Board of Directors to chart a path forward for the organization and support the rapidly evolving field.”
As Chief Medical Officer, Dr. Habtezion leads Pfizer’s Worldwide Medical & Safety organization, which is responsible for ensuring that patients, physicians and regulatory authorities are informed about the safe and appropriate use of Pfizer medications. Prior to joining Pfizer, she was a practicing physician and scientist Stanford University School of Medicine, where she led a large translation research lab focused on understanding disease mechanisms and identifying potential immune-based therapeutic targets for pancreatic and intestinal inflammatory diseases and their long-term complications, such as cancer.
“As a longtime academic researcher who has transitioned to industry, I greatly appreciate the PhRMA Foundation’s unique role in funding promising young scientists who conduct research that will help the biopharmaceutical industry’s future efforts to deliver new drugs to patients, said Dr. Habtezion. “I look forward to working with the Foundation’s board and staff to ensure the continued success of this respected organization.”
Dr. Biogen’s Radhakrishnan is one of the leading experts in medical strategy and health outcomes research who currently serves as Chief Medical Officer. She has extensive experience overseeing external engagement approaches with academic institutions, key opinion leaders, patient advocacy groups, payers and regulators. Prior to joining Biogen, Dr. Radhakrishnan has held leadership positions at Sanofi, Bioverativ, Bristol Myers Squibb, United Health Group and Cephalon.
“By investing in promising scientists and researchers, the PhRMA Foundation plays a fundamental role in helping the biopharmaceutical industry adapt to changing realities,” said Dr. Radhakrishnan. “With this evolution, there are many challenges that the PhRMA Foundation’s programs can help the industry address. One thing remains clear: we all need to come together across the industry to advance science and improve meaningful and measurable patient outcomes.”
Dr. Addona has been with Merck since 2008 and currently oversees the early stage pipeline, human studies and biomarker development. Previously, he was Vice President of Quantitative Biosciences, where he played a critical role in Merck’s drug discovery organization by leading a multidisciplinary team focused on preclinical programs across all therapeutic areas of the company. Prior to joining Merck, he held positions at Novartis and Praecis Pharmaceuticals.
“Our industry is at a turning point where emerging technologies and new therapeutic modalities are creating exciting opportunities in medicine and vaccine discovery and development,” said Dr. Addona. “I look forward to working with my fellow PhRMA Foundation Board members to advance innovative research and inspire a new and diverse generation of biopharmaceutical scientists.”
As a result of a change in the Foundation’s Articles of Association, Ms. Reilly joins the Board of the Foundation as an ex officio representative of PhMRA. Ms. Reilly has long been a leader in developing and advocating practical policy solutions that bring medicine to patients. She oversees PhRMA’s advocacy activities and alliance development work and provides strategic leadership to the organization and its members. Prior to her 20 years of service with PhRMA, she served as an advisor to the US House Committee on Commerce and a member of the House Ways and Means Committee.
“Research is critical to advancing new drugs and informing the policy environment that paves the way for patients to access those drugs,” Ms Reilly said. “The PhRMA Foundation fills a critical niche for the biopharmaceutical industry, helping to fuel innovation and develop thoughtful approaches to promote a value-driven health system.”
About the PhRMA Foundation
The PhRMA Foundation promotes biopharmaceutical innovation and value-driven healthcare by investing in the frontiers of research. The Foundation catalyzes the careers of promising researchers through competitive, peer-reviewed grants and grants in drug delivery, drug discovery, translational medicine, value assessment, and health outcomes research. Since its foundation in 1965, the Foundation has more than $110 million to more than 2,700 researchers from different backgrounds at more than 300 institutions. For more information, go to www.phrmafoundation.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/phrma-foundation-announces-new-members-of-board-of-directors-301689009.html
SOURCE PhRMA Foundation